Document is current
Any future updates will be listed below
-
Authors
McCarthy, Anne Marie
Kumar, Nitya Pradeep
He, Wei
Regan, Susan
Welch, Michaela
Moy, Beverly
Iafrate, A. John
Chan, Andrew T.
Bardia, Aditya
Armstrong, Katrina
-
Funding
Funding for this research was provided by:
American Cancer Society (131052-MRSG-17-144-01-CCE)
- License Information
-
More Information
Article History
Received: 14 November 2019
Accepted: 31 March 2020
First Online: 23 April 2020
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Partners Human Research Committee, Protocol # 2013P000848/MGH) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent for tumor genotyping received as part of clinical care was obtained from all study participants. Waiver of informed consent/authorization was granted for review of health/medical records for all participants included in the study.
: Not applicable.
: A. John Iafrate – Roche, Chugai, and Debiopharm Group (consultant/ advisory role); ArcherDx (stock ownership); Sanofi (funding). Andrew T. Chan – Bayer Pharma AG (consultant/advisory role and funding). Aditya Bardia – Genetech/Roche, Immunomedics, Daiichi, Novartis, Pfizer, Merck, Radius Health, Spectrum Pharma, and Taiho Pharma (consultant/advisory role); Biotheranostics (personal funding); <i>Breast Cancer Research and Treatment</i> Editorial Advisory Board member.
